Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

IMpower010 (ClinicalTrials.gov identifier: NCT02486718) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non-small cell lung cancer (NSCLC). We report DFS final analysis, second overall survival (OS) interim analysis, and safety with a

• Felip, E.
• Altorki, N.
• Zhou, C.
• Vallières, E.
• Csoszi, T.
• Vynnychenko, I. O.
• Goloborodko, O.
• Rittmeyer, A.
• Reck, M.
• Martinez-Marti, A.
• Kenmotsu, H.
• Chen, Y. M.
• Chella, A.
• Sugawara, S.
• Fu, C.
• Ballinger, M.
• Deng, Y.
• Srivastava, M. K.
• Bennett, E.
• Gitlitz, B. J.
• Wakelee, H. A.